The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma
Anticancer Research · 2025
DOI: 10.21873/anticanres.17797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Soichi Takeda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Antigens, Differentiation, Myelomonocytic, Liver Neoplasms, Carcinoma, Hepatocellular, Receptors, Cell Surface.
Abstract (Originalsprache)
BACKGROUND/AIM: This study aimed to identify predictors of therapeutic response to atezolizumab plus bevacizumab (Atez/Bev) in patients with advanced hepatocellular carcinoma (aHCC). PATIENTS AND METHODS: Of the 39 patients included in the study, 28 underwent a lactulose-mannitol test. Intestinal permeability (IP) was evaluated using the lactulose-to-mannitol ratio (LMR), serum soluble CD163 (sCD163), and soluble mannose receptor (sMR). The therapeutic response and its correlation with IP were evaluated. RESULTS: The median progression-free survival (PFS) and overall survival (OS) were 208 and 489 days, respectively. Regarding the best achieved treatment response, the objective response rate and disease control rate (DCR) were 39.2% and 67.8%, respectively, based on the Response Evaluation Criteria in Solid Tumors 1.1. The LMR was significantly higher in those with progressive disease (PD group) than in those achieving complete response, partial response, and stable disease [disease control (DC) group]. The optimal LMR cutoff was 5.24 for predicting ORR and PD. The low-LMR group showed significantly longer PFS than the high-LMR group. sCD163 and sMR were significantly higher in the PD group than in the DC group. sCD163 was found to be significantly associated with the DCR [odds ratio (OR)=14.3, 95%CI=1.47-138, p=0.022]. The patients were divided into two groups according to their median CD163 levels. The low-CD163 group showed significantly longer PFS and OS than the high-CD163 group. CONCLUSION: IP was associated with Atez/Bev response in HCC. sCD163 could be a predictive marker of Atez/Bev response in patients with aHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nara Medical University, Nara, Japan.
- Department of Gastroenterology, Nara Medical University, Nara, Japan; tadashin@naramed-u.ac.jp.
- Department of Evidence-Based Medicine, Nara Medical University, Nara, Japan.
- Clinical Research Center, Nara Medical University, Nara Medical University, Nara, Japan.
Zitieren
APA
Takeda, S., Namisaki, T., Koizumi, A., Takaya, H., Tsuji, Y., Shibamoto, A., Iwai, S., Inoue, T., Fujinaga, Y., Nishimura, N., Sato, S., Kitagawa, K., Kaji, K., Mitoro, A., Asada, K., & Yoshiji, H. (2025). The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17797
Vancouver
Takeda S, Namisaki T, Koizumi A, Takaya H, Tsuji Y, Shibamoto A, et al. The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma. Anticancer Research. 2025. doi:10.21873/anticanres.17797
BibTeX
@article{Takeda2025,
author = {Takeda, Soichi and Namisaki, Tadashi and Koizumi, Aritoshi and Takaya, Hiroaki and Tsuji, Yuki and Shibamoto, Akihiko and Iwai, Satoshi and Inoue, Takashi and Fujinaga, Yukihisa and Nishimura, Norihisa and Sato, Shinya and Kitagawa, Koh and Kaji, Kosuke and Mitoro, Akira and Asada, Kiyoshi and Yoshiji, Hitoshi},
title = {The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17797}
}
EUVIMED